Medpace Holdings, Inc. shares have recently benefited from a buyers' comeback, which was accompanied by a rise in volumes and volatility. This situation suggests a continuation of the upward dynamic. Investors should benefit from the breakout of the $ 109.9 level to target the $ 150.
The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
The company has solid fundamentals for a short-term investment strategy.
Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 40% by 2022.
Thanks to a sound financial situation, the firm has significant leeway for investment.
There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
The group usually releases upbeat results with huge surprise rates.
Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
Over the last twelve months, the sales forecast has been frequently revised upwards.
For the past twelve months, EPS forecast has been revised upwards.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
The tendency within the weekly time frame is positive above the technical support level at 70.16 USD
The stock is close to a major daily resistance at USD 101.95, which should be gotten rid of so as to gain new appreciation potential.
The company benefits from high valuations in earnings multiples.
The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.